Teprotumumab-Trbw

Introduction Overview

Generic Name

teprotumumab-trbw

Brand Name

Tepezza

Dosage Form

intravenous infusion

Drug Class

Growth hormone receptor blockers

Pharmacokinetics

Absorption: Tepezza is administered via intravenous infusion, which bypasses gastrointestinal absorption processes and ensures complete bioavailability. The infusion is typically given over 60 to 90 minutes, allowing immediate availability of the drug into systemic circulation. The dosing regimen consists of an initial dose followed by maintenance doses every three weeks for a total of eight infusions, facilitating a steady-state concentration suitable for continuous therapeutic effect.

Distribution: As a monoclonal antibody targeting IGF-1 receptors, Tepezza primarily distributes in the vascular and interstitial compartments. Its large molecular size restricts penetration beyond these spaces; however, it effectively reaches the orbital tissues where IGF-1R is overexpressed in Thyroid Eye Disease (TED). The volume of distribution is limited, characteristic of monoclonal antibodies, correlating with plasma volume and extravascular distribution.

Metabolism: Tepezza, like other monoclonal antibodies, is metabolized via catabolic pathways predominantly through proteolytic degradation. This process occurs systemically and within target tissues, breaking the protein down into small peptides and amino acids which are then recycled or excreted. Hepatic metabolism involving cytochrome P450 enzymes is minimal due to the nature of monoclonal antibodies.

Elimination: The elimination half-life of Tepezza averages approximately 20 days. Clearance is primarily through reticuloendothelial system-mediated catabolism of antibody-protein complexes following receptor binding or nonspecific pathways. The drug is cleared slowly, supporting the three-week dosing interval. Complete elimination occurs over approximately 80 to 100 days post final dose, correlating with 4 to 5 half-lives. No renal or hepatic clearance predominates, and elimination is not influenced significantly by impaired renal or hepatic function.

Dosage Forms

Available Dosage Forms: Tepezza is supplied as a 500 mg single-dose vial of lyophilized powder for reconstitution.

Dosages for Adults and Adolescents: The recommended dosing regimen for adults with Thyroid Eye Disease involves an initial intravenous infusion of 10 mg/kg followed by seven maintenance infusions of 20 mg/kg administered every three weeks, totaling eight doses. Each infusion is administered over 60 to 90 minutes.

Specific Patient Populations: There is limited data on dosing adjustments for pediatric populations; Tepezza use is primarily indicated for adult patients with TED. Caution is advised in patients with pre-existing inflammatory bowel disease or diabetes mellitus due to potential exacerbation or hyperglycemia. No available dosing modifications are specified for renal or hepatic impairment, given the drug's metabolic pathways.

Mechanism Of Action

Tepezza (teprotumumab-trbw) is a fully human monoclonal antibody that selectively binds to and inhibits the insulin-like growth factor-1 receptor (IGF-1R), a cell-surface receptor implicated in the pathogenesis of Thyroid Eye Disease (TED). By blocking IGF-1R activation, Tepezza disrupts downstream signaling pathways that promote inflammation and tissue remodeling in the orbit.

The binding of Tepezza to IGF-1R inhibits receptor activation and subsequent intracellular signaling cascades involving the PI3K/AKT and MAPK pathways, which are central to cellular proliferation, differentiation, and survival. This blockade prevents the expansion and activation of orbital fibroblasts, immune cell infiltration, and excessive glycosaminoglycan production leading to tissue swelling and fibrosis behind the eye.

Clinically, this targeted molecular interference results in decreased inflammation, reduced orbital tissue volume, and mitigation of proptosis and diplopia that characterize TED. Tepezza's action contrasts with conventional immunosuppressants by directly targeting a receptor central to disease mechanism, rather than broadly suppressing immune response.

Multiple clinical studies, notably the Phase 3 OPTIC trial, have demonstrated that Tepezza significantly reduces proptosis and improves diplopia by attenuating the autoimmune-mediated activation of orbital tissues. Comparative analysis shows Tepezza's unique mechanism provides benefits beyond corticosteroids or radiotherapy, offering a disease-modifying treatment rather than symptom control alone.

Pharmacological Actions

Selective inhibition of insulin-like growth factor-1 receptor (IGF-1R) signaling.
Reduction of orbital fibroblast activation and proliferation.
Suppression of inflammation and immune-mediated tissue remodeling in thyroid eye disease.
Prevention of glycosaminoglycan overproduction and expansion of orbital connective tissue.
Decrease of proptosis (eye bulging) and improvement of diplopia (double vision).
Modulation of autoimmune processes involved in Graves' ophthalmopathy.
Reduction of orbital tissue swelling and associated pain and redness.
Does not broadly suppress the immune system, offers targeted therapy.
Pharmacodynamic effects leading to long duration of action consistent with dosing intervals.
Potential to preserve or improve visual function by reducing mechanical compression.
Interferes with pathogenic signaling pathways implicated in TED progression.
Does not exhibit cytotoxic effects on non-target tissues at therapeutic doses.
Demonstrated efficacy in both active and chronic phases of thyroid eye disease.
Improves patient-reported symptoms of eye discomfort and appearance.

Therapeutic Or Clinical Uses

Treatment of thyroid eye disease (TED) to reduce symptoms including proptosis and diplopia.
Management of inflammation, eye pain, redness, and swelling associated with TED.
Reduction of tissue expansion behind the eyes in patients with Graves’ ophthalmopathy.
Improvement of double vision (diplopia) severity grades in TED patients.
Usage in new-onset as well as chronic TED irrespective of disease duration or activity.
Treatment aimed at altering underlying disease mechanisms rather than symptomatic relief alone.
Alternative to corticosteroids and surgical interventions for TED.
Therapy to improve appearance and visual function in affected patients.
Employed in patients who have failed or are unsuitable for traditional therapies.
Potential to prevent progression of TED-related orbital complications.
Use in adult patients with autoantibody-mediated orbital inflammation.
Improvement of quality of life in patients with thyroid eye disease.
Adjunct to endocrinological management of Graves' disease related eye involvement.
FDA-approved indication specifically for TED treatment.
Reduction of long-term ocular morbidity associated with thyroid eye disease.

Side Or Adverse Effects

Muscle spasms occurring in approximately 25% of patients.
Nausea reported in around 17% of treated individuals.
Diarrhea events seen in about 12% of patients receiving Tepezza.
Headache experienced by roughly 8% of patients during therapy.
Fatigue or tiredness reported in 12% of cases.
Hyperglycemia or elevated blood sugar in approximately 10%, necessitating monitoring.
Alopecia or hair loss reported in 13% of patients.
Hearing problems including hearing loss or impairment in about 10% of patients.
Dry skin and dermatologic changes in 8% of treated individuals.
Altered taste sensation (dysgeusia) noted in 8% of patients.
Weight decrease observed in approximately 6% of patients.
Nail disorders such as brittleness or discoloration reported in 5%.
Infusion-related reactions ranging from mild to moderate severity.
Serious allergic reactions including potential anaphylaxis requiring emergency management.
Potential exacerbation of inflammatory bowel disease symptoms.

Precautions

Patients with pre-existing inflammatory bowel disease should be carefully monitored for exacerbations.
Monitor blood glucose levels in patients with diabetes or predisposition to hyperglycemia.
Evaluate patients for hearing impairment prior to, during, and following treatment.
Use effective contraception during therapy and for at least six months post-treatment due to potential fetal harm.
Assess for potential infusion reactions during and shortly after infusions with emergency protocols in place.
Caution in patients with a history of allergic reactions to similar monoclonal antibodies.
Monitor for gastrointestinal symptoms indicative of bowel inflammation or bleeding.
Regularly monitor clinical signs suggestive of infusion-related adverse events.
Avoid use during pregnancy unless potential benefit justifies risks to the fetus.
Breastfeeding is not recommended during therapy without professional guidance.
Patients should report symptoms such as sudden diarrhea, cramping, or rectal bleeding immediately.
Adjustment or discontinuation of therapy may be necessary in case of severe adverse events.
Implement glycemic control measures prior to and during treatment in diabetic patients.
Evaluate risk-benefit ratio for individual patients, especially those with comorbid autoimmune disorders.
Ensure comprehensive patient education regarding potential side effects and required monitoring.

Warnings

Risk of infusion reactions during or within 1.5 hours post-infusion, which can be managed with corticosteroids and antihistamines.
Potential exacerbation of pre-existing inflammatory bowel disease with serious flare-ups possible.
Hyperglycemia risk necessitating blood glucose monitoring before and during treatment.
Possibility of severe, potentially permanent hearing loss or impairment; audiologic monitoring recommended.
Use during pregnancy carries risk of fetal harm; contraception is mandatory during therapy and for six months afterward.
Serious allergic reactions, including anaphylaxis, may occur; emergency medical support should be readily available.
Not recommended for use in breastfeeding due to unknown risks to infant.
Patients with diabetes or increased risk for hyperglycemia should maintain optimal glycemic control.
Close surveillance suggested for gastrointestinal symptoms suggestive of serious bowel inflammation.
Was not designed for pediatric use; safety in children has not been established.
Dose-related immunogenicity has not been reported but clinical vigilance is necessary.
Monitor for signs of immune system compromise or secondary infections.
Consider discontinuation if severe adverse effects, especially infusion reactions, occur.
Ensure that therapy is provided by healthcare professionals experienced in monoclonal antibody infusions.
Potential for interference with concomitant immunomodulatory therapies.

Contraindication

Known hypersensitivity or allergy to teprotumumab or any excipient in the formulation.
Active severe infusion reactions or anaphylaxis to prior doses of monoclonal antibodies targeting IGF-1R.
Pregnancy due to risk of fetal harm without adequate contraception measures.
Severe uncontrolled hyperglycemia prior to initiation.
Pre-existing severe inflammatory bowel disease with acute exacerbation.
Patients with unresolved or severe infections requiring systemic therapy.
Use in pediatric patients below approved age due to lack of safety and efficacy data.
Concurrent participation in other investigational drug trials that may interfere with Tepezza therapy.
Use in patients with hypersensitivity to any components of the reconstitution or infusion preparation.
Severe renal or hepatic impairment if deemed at increased risk by treating physician due to lack of data.
Patients with a history of severe systemic autoimmune diseases without adequate control.
Use alongside other monoclonal antibodies that may have overlapping toxicity profiles unless clearly justified.
Administration without appropriate medical supervision and monitoring capability.
Individuals with known hypersensitivity to other monoclonal antibodies without prior testing.
Contraindicated if active malignancy is present or suspected without oncology consultation.

Drug Interactions

No significant cytochrome P450-mediated drug interactions reported due to monoclonal antibody nature.
Potential interaction with immunosuppressive agents may increase risk of infection or immunosuppression.
Concurrent use with other biologics targeting immune pathways may augment immunosuppressive effects.
No known interactions with oral hypoglycemic agents, but blood glucose must be monitored due to hyperglycemia risk.
Limited data exist on interactions with vaccines; immunization status should be assessed prior to therapy.
No direct interaction with anticoagulants or antiplatelet medications reported.
No evidence of interaction with anticonvulsants, antibiotics, or commonly used cardiovascular drugs.
Possible alteration of immune response to infections or vaccines in patients receiving Tepezza.
Patients should disclose use of over-the-counter supplements and herbal products as data are limited.
No known effects on pharmacokinetics of other monoclonal antibodies or protein-based therapies.
Concomitant corticosteroid use must be cautiously managed given overlapping side effect profiles.
No documented interaction with common analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs).
Potential interference with clinical laboratory assays that measure IGF-1 levels.
Clinicians should monitor for additive toxicity when combining Tepezza with other immunomodulators.
Future drug evaluations should consider Tepezza’s long half-life and potential for prolonged biological activity.

Preparations Of The Drug

Tepezza is supplied as a 500 mg lyophilized powder in a single-dose vial.
Requires reconstitution with 20 mL sterile water for injection prior to dilution.
Reconstituted solution must be further diluted in an appropriate volume of 0.9% Sodium Chloride Injection for infusion.
Single-dose vials are for intravenous infusion only and are intended for single use to prevent contamination.
Storage of unopened vials is refrigerated at 2°C to 8°C (36°F to 46°F) protected from light; do not freeze.
After reconstitution and dilution, the solution is stable for up to 4 hours at room temperature or up to 48 hours refrigerated at 2°C to 8°C protected from light.
Allow refrigerated diluted solutions to reach room temperature before administration.
The infusion is administered over 60 to 90 minutes by a healthcare professional.
Discard any unused portion after infusion to maintain sterility and safety.
Packaging includes vial labels with J-code (J3241) relevant for billing and reimbursement purposes.
Supplied by Horizon Therapeutics Ireland DAC and distributed by Horizon Therapeutics USA, Inc.
Preparation should adhere strictly to aseptic techniques and institutional protocols.
Detailed prescribing information and package insert should be consulted for preparation and administration guidance.
Patients should receive therapy only in settings with adequate emergency support for infusion reactions.
Preparation and administration instructions emphasize protection from light and control of temperature.